Ocular Therapeutix
OCUL
135 hedge funds and large institutions have $224M invested in Ocular Therapeutix in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 42 increasing their positions, 38 reducing their positions, and 17 closing their positions.
150% more call options, than puts
Call options by funds: $4.99M | Put options by funds: $1.99M
53% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 17
11% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 38
6% more funds holding
Funds holding: 127 → 135 (+8)
3.81% more ownership
Funds ownership: 52.24% → 56.05% (+3.8%)
5% more capital invested
Capital invested by funds: $214M → $224M (+$10.4M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.09M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$4.77M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$4.32M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$3.84M |
| 5 |
Axa
Paris,
France
|
+$2.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.64M |
| 2 |
D.E. Shaw & Co
New York
|
-$2.64M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$2.23M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.94M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.64M |
OCUL Hedge Fund Activity: Q2 2023 in Review
135 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q2 2023, worth a combined $224M — up 4.8% from $214M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new OCUL positions and 17 closed out — a net gain of 9 holders — while 42 added to existing stakes and 38 trimmed.
The largest buyer was Millennium Management, adding an estimated $8.09M. The largest seller was Morgan Stanley, cutting an estimated $5.64M.
- 135 institutional investors held Ocular Therapeutix (OCUL) as of Q2 2023, up from 127 in Q1 2023.
- Funds reported $224M of Ocular Therapeutix stock for Q2 2023, up 4.8% quarter-over-quarter.
- 26 funds opened new Ocular Therapeutix positions in Q2 2023 and 17 closed out, a net change of +9 holders.
- The largest Ocular Therapeutix buyer in Q2 2023 was Millennium Management, an estimated $8.09M added.
- The largest Ocular Therapeutix seller in Q2 2023 was Morgan Stanley, an estimated $5.64M sold.
Based on aggregated 13F filings for Q2 2023.